Compare
Ernexa Therapeutics Inc. vs CDT Equity Inc. vs AEON Biopharma, Inc. vs GeoVax Labs, Inc.
| Latest fiscal year | Ernexa Therapeutics Inc. ERNA | CDT Equity Inc. CDT | AEON Biopharma, Inc. AEON | GeoVax Labs, Inc. GOVX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $2.49M |
| Revenue growth (YoY) | n/a | n/a | n/a | -37.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -869.3% |
| Net margin | n/a | n/a | n/a | -862.3% |
| Net income | -$14.08M | -$39.22M | -$39.22M | -$21.46M |
| EPS (Diluted) | -$2.24 | -$1177.89 | -$3.95 | n/a |
| Operating cash flow | -$7.02M | -$15.55M | -$17.31M | -$21.47M |
| Free cash flow | -$7.05M | n/a | -$17.31M | -$21.50M |
| Cash & equivalents | n/a | $1.51M | $3.01M | $3.09M |
| Total assets | $5.83M | $5.65M | $5.56M | $6.34M |
| Total liabilities | $3.43M | $12.82M | $60.59M | $2.52M |
| Shareholders' equity | $2.40M | -$7.17M | -$55.03M | $3.83M |
| Return on year-end equity | -586.6% | n/a | n/a | -561.2% |
| Shares outstanding | 7.85M | 92.1K | 12.11M | 1.73M |
Revenue, most recent five fiscal years
| Fiscal year | Ernexa Therapeutics Inc. | CDT Equity Inc. | AEON Biopharma, Inc. | GeoVax Labs, Inc. |
|---|---|---|---|---|
| Latest | $582.0K Ended 2024-12-31 | n/a | n/a | $2.49M Ended 2025-12-31 |
| 1 year earlier | $68.0K Ended 2023-12-31 | n/a | n/a | $3.95M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2022-12-31 | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $81.5K Ended 2022-12-31 |
| 4 years earlier | $5.80M Ended 2020-12-31 | n/a | n/a | $385.5K Ended 2021-12-31 |